

REVIEW

Open Access

Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma

Reason Wilken¹, Mysore S Veena^{1,3}, Marilene B Wang^{1,2}, Eri S Srivatsan^{1,3*}

Abstract

Curcumin (diferuloylmethane) is a polyphenol derived from the *Curcuma longa* plant, commonly known as turmeric. Curcumin has been used extensively in Ayurvedic medicine for centuries, as it is nontoxic and has a variety of therapeutic properties including anti-oxidant, analgesic, anti-inflammatory and antiseptic activity. More recently curcumin has been found to possess anti-cancer activities via its effect on a variety of biological pathways involved in mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis and metastasis. Curcumin has shown anti-proliferative effect in multiple cancers, and is an inhibitor of the transcription factor NF- κ B and downstream gene products (including c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF- α , interleukins and MMP-9). In addition, curcumin affects a variety of growth factor receptors and cell adhesion molecules involved in tumor growth, angiogenesis and metastasis. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and treatment protocols include disfiguring surgery, platinum-based chemotherapy and radiation, all of which may result in tremendous patient morbidity. As a result, there is significant interest in developing adjuvant chemotherapies to augment currently available treatment protocols, which may allow decreased side effects and toxicity without compromising therapeutic efficacy. Curcumin is one such potential candidate, and this review presents an overview of the current in vitro and in vivo data supporting its therapeutic activity in head and neck cancer as well as some of the challenges concerning its development as an adjuvant chemotherapeutic agent.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common form of cancer worldwide and represents approximately 5% of all cancers diagnosed annually in the United States [1,2]. Every year more than 30,000 cases of oral and pharyngeal cancer are diagnosed, and over 8,000 individuals die of the disease. If the definition of HNSCC is expanded to include laryngeal cancers, the number of annually diagnosed cases grows to over 42,000 individuals and results in over 12,000 deaths per year in the United States [3].

The development of head and neck malignancies is strongly associated with certain risk factors such as tobacco use, alcohol consumption and environmental exposures (such as EBV infection in the case of

nasopharyngeal carcinoma). Additionally, human papilloma virus (HPV) infection is emerging as a causative agent for HNSCC and may account for the increased incidence of this malignancy in patients who do not have histories of alcohol or tobacco usage [4]. By virtue of their inconspicuous location, many cases of HNSCC are not discovered until the cancer is at a later stage, not uncommonly until after spread to lymph nodes in the neck. A growing tumor in the head and neck region may not cause any discernable symptoms and a large portion of earlier-stage oral tumors are discovered incidentally, often by dental providers.

Standard treatment regimens for head and neck cancer depend on the stage of the disease. Early stage (stage I and II) tumors are treated primarily with surgery or radiotherapy, with both modalities resulting in similar local control and survival rates. Radiation may also be used postoperatively when surgical margins are close or positive, or if perineural or lymphovascular invasion by

* Correspondence: esrivats@ucla.edu

¹Department of Surgery, VA Greater Los Angeles Healthcare System, West Los Angeles, CA, USA

Full list of author information is available at the end of the article

tumor is found. More advanced (stage III and IV) cancers often require multi-modality therapy with surgery, radiation and chemotherapy which can result in very high morbidity [5]. Concurrent chemoradiation (CRT) for locoregionally advanced HNSCC is the preferred treatment in cases of unresectable disease or instances when surgical resection would result in an unacceptable functional loss for the patient. Recent years have seen a trend towards organ-sparing therapies of chemotherapy and radiation for resectable cancers of the oropharynx, hypopharynx and larynx [6].

Platinum-based agents form the backbone of the standard chemotherapeutic regimens for head and neck cancer. Cisplatin (cis-diamminedichloroplatinum) is a widely used drug in the class of platinum-based chemotherapies (which also includes carboplatin & oxaliplatin). The platinum compounds work by the formation of DNA crosslinks within cells, leading to apoptosis and cellular senescence. The efficacy of cisplatin in HNSCC is greatly increased when combined with other chemotherapeutic agents, such as taxanes (paclitaxel and docetaxel) and 5-fluorouracil (5-FU) (Table 1) [7-10].

The potential adverse effects from the treatment for HNSCC are numerous. Radical surgery can result in disfigurement & functional impairment, but even the organ-preserving treatment methods of radiation and chemotherapy may result in a host of negative side effects, some permanent [11]. Common side effects of radiotherapy include mucositis, oral candidiasis, loss of taste and xerostomia, which may be permanent due to the damaging effect of radiation on the salivary glands

[11]. Osteoradionecrosis of bones within the radiation field (most commonly the mandible) may occur as a result of damage to the bone vasculature and osteocytes and is one of the most serious complications of radiotherapy [12]. The toxic effects of platinum-based chemotherapy are dose dependent and include renal, otologic, and bone marrow suppressive sequelae (Table 1) [7-10].

Despite continuing research and advances in treatment, the clinical outcomes and overall survival rates for HNSCC have not improved significantly over the last several decades, with the overall 5 year survival rate as low as 50% [1,2,13]. As a result, there has been continuing investigation into potential alternative and less toxic therapies for head and neck cancer, with the aim of achieving a more favorable clinical outcome while reducing treatment morbidity. The class of molecularly targeted therapies against the epidermal growth factor receptor (EGFR) is one such example, as EGFR is over-expressed in a number of head and neck cancers. Cetuximab is an anti-EGFR monoclonal antibody that was approved by the Food and Drug Administration in 2004 for the treatment of advanced colon cancer. In 2006, Cetuximab was approved for use in head and neck squamous cell carcinoma—both in combination with radiotherapy for advanced HNSCC as well as single-agent therapy for platinum-refractory head and neck cancer (Table 1). Several studies of cetuximab as an adjuvant agent with radiotherapy have demonstrated improved locoregional control and statistically significant increases in both progression-free and overall survival [14,15].

Table 1 Current chemotherapeutic models in head and neck cancer

Agent	Mechanism	Mode of Usage in HNSCC	Significant Adverse Effects	Reference
Platinum agents (Cisplatin/Carboplatin)	Formation of DNA adducts, induction of apoptosis and senescence	Cisplatin/Carboplatin single-agent Cisplatin/Carboplatin in combination with 5-Fluorouracil	Nephrotoxicity (acute renal failure, chronic renal insufficiency) Ototoxicity (high-frequency hearing loss) Neurotoxicity (peripheral neuropathy) Hematologic (myelosuppression) Gastrointestinal (nausea, vomiting) Electrolyte disturbances (hypomagnesiumia/hypokalemia/hypocalcemia)	[8-12]
5-Fluorouracil	Anti-metabolite (pyrimidine analog, inhibits thymidylate synthase)	5-Fluorouracil in combination with Cisplatin/Carboplatin, and with or without Paclitaxel	Cardiac toxicity (angina, myocardial ischemia), Gastrointestinal (nausea, vomiting, ulcers), Hematologic (myelosuppression), Thrombophlebitis, Dermatologic (rash)	[8-10]
Taxanes (Paclitaxel/Docetaxel)	Anti-microtubular agent (inhibitor of mitosis)	Paclitaxel in combination with Carboplatin/Cisplatin, and with or without 5-Fluorouracil	Cardiovascular (hypotension, EKG changes) Gastrointestinal (mucositis, nausea, vomiting) Hematologic (neutropenia, leukopenia, thrombocytopenia), Neuromuscular (peripheral neuropathy, myalgias), Hepatic (elevated liver enzymes)	[9,10]
Cetuximab	Anti-EGFR monoclonal antibody	Cetuximab plus radiation therapy Single-agent cetuximab in platinum refractory HNSCC Phase I/II trial of cetuximab plus 5-FU and platinum agents (on going)	Infusion reaction Dermatologic (acneform rash, pruritis) Gastrointestinal (abdominal pain, constipation, diarrhea, nausea, vomiting), Respiratory (dyspnea, cough), Neuromuscular weakness	[14-17,202]

The addition of cetuximab to standard platinum-based chemotherapy in platinum-resistant recurrent or metastatic head and neck cancer has also been studied and demonstrated increased treatment efficacy and improved overall survival without a significant increase in toxicity [16,17].

Curcumin, an Indian spice with antioxidant, anti-inflammatory and anti-cancer properties, has shown promise both as a potential chemopreventive agent as well as a novel adjuvant treatment for head and neck malignancies. This review will discuss the biological properties of curcumin, with emphasis on the molecular pathways modulated by the spice that may prove useful in the treatment of head and neck squamous cell carcinoma.

Curcumin

Curcumin (diferuloylmethane) is the chief component of the spice turmeric and is derived from the rhizome of the East Indian plant *Curcuma longa*. *Curcuma longa* is a member of the Zingiberaceae (ginger) family of botanicals and is a perennial plant that is native to Southeast Asia [18]. Turmeric contains a class of compounds known as the curcuminoids, comprised of curcumin, demethoxycurcumin and bisdemethoxycurcumin (Figure 1) [19]. Curcumin is the principal curcuminoid and comprises approximately 2-5% of turmeric; it is responsible for the yellow color of the spice as well as the majority of turmeric's therapeutic effects [18]. Aside from being employed as a flavoring and coloring agent in food,

turmeric has also been widely used in Ayurvedic medicine for its anti-oxidant, antiseptic, analgesic, antimalarial and anti-inflammatory properties [20]. Curcumin has been consumed as a dietary supplement for centuries and is considered pharmacologically safe [21].

Antioxidant Activity

Curcumin is a lipophilic polyphenol and thus is insoluble in water, but is readily soluble in organic solvents such as dimethylsulfoxide, acetone and ethanol [20,22]. The antioxidant activity of the curcuminoids comes by virtue of their chemical structure. The curcuminoids consist of two methoxylated phenols connected by two α , β unsaturated carbonyl groups that exist in a stable enol form [23]. Curcumin has been shown to inhibit lipid peroxidation using linoleate, a polyunsaturated fatty acid that is able to be oxidized and form a fatty acid radical. It has been demonstrated that curcumin acts as a chain-breaking antioxidant at the 3' position, resulting in an intramolecular Diels-Alder reaction and neutralization of the lipid radicals [24]. In addition to inhibiting lipid peroxidation, curcumin demonstrates free radical-scavenging activity. It has been shown to scavenge various reactive oxygen species produced by macrophages (including superoxide anions, hydrogen peroxide and nitrite radicals) both in vitro as well as in vivo using rat peritoneal macrophages as a model [25,26]. Inducible nitric oxide synthase (iNOS) is an enzyme found in macrophages that generates large amounts of NO to provide the 'oxidative burst' necessary for defense against pathogens. iNOS is induced in response to an oxidative environment, and the NO generated can react with superoxide radicals to form peroxynitrite, which is highly toxic to cells. It has been shown that curcumin downregulates the iNOS activity in macrophages, thus reducing the amount of reactive oxygen species (ROS) generated in response to oxidative stress [27,28]. Additional studies in microglial cells (brain macrophage analogs) demonstrated reduced NO generation and protection of neural cells from oxidative stress following curcumin treatment, thus the spice and may be useful in reducing the neuroinflammation associated with degenerative conditions such as Alzheimer's disease [29-31].

Anti-inflammatory Activity: Effect on NF- κ B Pathway

Curcumin has been shown to suppress the activation of NF- κ B, an inducible transcription factor that regulates the expression of a host of genes involved in inflammation, cellular proliferation and cell survival [32-57]. Genes regulated by NF- κ B include cyclooxygenase-2 (COX-2), I κ B α , TNF- α , cyclin D1, ICAM-1, c-myc, Bcl-2, MMP-9, inducible nitric oxide synthase (iNOS), and interleukins including IL-6 and IL-8 [19,35,36,58,59].




Figure 1 Structure of the curcuminoids curcumin, demethoxycurcumin and bisdemethoxycurcumin.

NF- κ B expression is involved in cellular responses to stressful stimuli such as cytokines, UV irradiation, free radicals, hypoxia (including cigarette smoke) and infectious antigens [60-64]. Activation of NF- κ B is increased in many cancers, and is associated with various steps in the development of malignancy such as expression of anti-apoptotic genes, angiogenesis, tumor promotion and metastasis [65]. Studies from our laboratory as well as others have demonstrated constitutive expression of NF- κ B in head and neck squamous cell carcinoma [45,48,53,66,67].

NF- κ B is a heterodimeric protein composed of five subunits: RelA (p65), RelB, c-Rel, NF- κ B1 (p50 and p105) and NF- κ B2 (p52) [68]. The complex is retained in the cytoplasm in an inactive form by I κ B (inhibitor of NF- κ B), which is composed of α and β subunits. Upon receipt of the appropriate chemical signals that initiate NF- κ B activation, several steps are required to free NF- κ B from this inhibitory binding. I κ B must be phosphorylated at its α subunit by I κ K (inhibitor kappa B kinase) which results in ubiquitination and degradation of the phosphorylated I κ B α and the release of NF- κ B from its stationary location in the cytoplasm. The unbound NF- κ B is then available for transport into the nucleus where it may bind to DNA and activate transcription.

Curcumin's inhibitory effect on the NF- κ B pathway is central to providing the compound with its anti-inflammatory properties. Curcumin blocks the I κ K-mediated phosphorylation and degradation of I κ B α , thus NF- κ B remains bound to I κ B α in the cytoplasm and is not able to enter the nucleus to activate transcription [34,35,53]. Studies involving suppression of NF- κ B activity have demonstrated a subsequent down-regulation of COX-2 and iNOS and decreased production of inflammatory markers [33,36,41]. Consistent with its effect on NF- κ B, curcumin has been shown to inhibit the production of inflammatory cytokines by activated monocytes and macrophages, including COX-2, lipoxygenase (LOX), iNOS, monocyte chemoattractant protein-1 (MCP-1), monocyte inflammatory protein-1 (MIP-1 α) and interleukins including IL-1, -2, -6, -8, and -12 [69,70].


In addition to inhibiting NF- κ B activation, curcumin also has suppressive effects on other pathways involved in inflammation. The arachidonic acid pathway for eicosanoid biosynthesis is an important participant in the inflammatory response, generating a host of reactive lipid products including leukotrienes, prostaglandins, prostacyclins and thromboxanes. Curcumin has been shown to decrease the metabolism of arachidonic acid by downregulating the activity of LOX and COX-2, both at the transcriptional level as well as via post-translational enzyme inhibition [70-72]. More recently, it has been demonstrated that curcumin inhibits prostaglandin E2 biosynthesis through direct inhibition of the

microsomal prostaglandin E2 synthase-1 enzyme [73]. In addition, the free-radical scavenging activity of curcumin also contributes to its anti-inflammatory properties by decreasing the amount of oxidative stress that can trigger the inflammatory cascade. The anti-inflammatory properties of curcumin have been investigated in a number of disease entities such as Alzheimer's disease, cardiovascular disease, diabetes, asthma, inflammatory bowel disease, arthritis, pancreatitis and renal disease [74-90].

Anti-cancer Activity: Suppression of Carcinogenesis

Curcumin has been studied in multiple human carcinomas including melanoma, head and neck, breast, colon, pancreatic, prostate and ovarian cancers [45,48,53,91-96]. Epidemiological studies attribute the low incidence of colon cancer in India to the chemopreventive and antioxidant properties of diets rich in curcumin [97]. The mechanisms by which curcumin exerts its anti-cancer effects are comprehensive and diverse, targeting many levels of regulation in the processes of cellular growth and apoptosis. Besides the vertical effects of curcumin on various transcription factors, oncogenes and signaling proteins, it also acts at various temporal stages of carcinogenesis—from the initial insults leading to DNA mutations through the process of tumorigenesis, growth and metastasis (Figure 2). Because of the far-reaching effects and multiple targets of curcumin on the cell growth regulatory processes, it holds much promise as a potential chemotherapeutic agent for many human cancers.

Curcumin's potent anti-oxidant and free-radical quenching properties play an important role in the inhibitory effects of the compound on the initial stages of carcinogenesis. It has been shown that curcumin has the ability to suppress UV irradiation-induced DNA mutagenesis and induction of cellular SOS functions [98]. In addition to the inhibitory effects on the production of nitric oxide (NO) and the ability to scavenge DNA-damaging superoxide radicals, curcumin also affects both the Phase I and Phase II enzymes of the hepatic cytochrome p450 enzyme system involved in the oxidation and detoxification of toxic substances. Curcumin has been shown to inhibit the Phase I enzymes (including cytochrome p450 isoforms and p450 reductase) which are induced in response to toxin exposure and create a host of carcinogenic metabolites that contribute to DNA adduct formation during the oxidation of such substances [99]. Conversely, curcumin induces the Phase II enzymes involved in detoxification of toxic metabolites (including glutathione S-transferase, glutathione peroxidase and glutathione reductase) [100]. Curcumin's inhibitory effect on carcinogenesis has been demonstrated in several animal models of various tumor types including oral cancer, mammary carcinoma and intestinal tumors [101-103].



Effect on Transcription Factors NF-κB and AP-1

NF-κB and AP-1 are two transcription factors intimately involved in the cellular pathways leading to tumorigenesis. As discussed earlier, NF-κB expression is induced by various stressful stimuli (including oxidative stress, cytokines such as TNF-α and IL-1, UV irradiation and infectious antigens) and results in expression of genes involved in inflammation and cellular proliferation. AP-1 is a transcription factor composed of dimers or heterodimers from the Jun, Fos, and ATF families of proteins that binds at a specific DNA site known as TPA-responsive elements (TREs) containing the consensus sequence 5'-TGAG/CTCA-3' [104]. AP-1 is also activated in response to tumor promoters, pro-inflammatory cytokines, UV irradiation and oxidative stress, and the activation of both transcription factors was shown to be required for maintaining transformed tumorigenic phenotypes in mouse epidermal JB6 cells [105]. Like

NF-κB, AP-1 regulates the expression of a variety of genes involved in control of the cell cycle and apoptosis. The c-Jun domain of AP-1 is a positive regulator of cyclin D1 expression, contributing to the induction of a tumorigenic phenotype. c-Jun is also a negative regulator of p53 expression and fibroblast cells expressing constitutive levels of c-Jun express lower levels of both p53 and the p53-regulated cyclin-dependant kinase inhibitor p21^{Cip1/Waf1} and fail to undergo growth arrest following UV exposure [106]. In addition, c-Jun has been shown to down-regulate the expression of p16 and antagonize JunB mediated p16 activation [107].

Curcumin has an inhibitory effect on both NF-κB and AP-1 activation. As reviewed above, curcumin's effect on NF-κB is mediated through inhibition of IκK and results in inactive NF-κB remaining bound to IκBα in the cytoplasm. As a result, curcumin has been shown to suppress the expression of a variety of NF-κB regulated

gene products involved in carcinogenesis and tumor growth including cyclin D1, VEGF, COX-2, c-myc, Bcl-2, ICAM-1 and MMP-9 [108,109]. In the case of AP-1, curcumin has been shown to downregulate the production of c-jun mRNA in vivo. Thus, it is proposed that decreased production of the Jun-Fos complex is the underlying mechanism for the decreased AP-1 transcriptional activity in the presence of curcumin and unlike with other inhibitors of Ap-1, this effect is independent of the redox status of the cell [110].

Effect on Cell Cycle Regulation and Apoptosis

Cellular growth and proliferation is a highly regulated event in normal cells, and derangements of the cell cycle can lead to uncontrolled proliferation and contribute to the malignant phenotype of tumor cells. The mammalian cell cycle consists of four main stages: G1, S, G2 and M, with G1 and G2 being referred to as “gap” phases between the events of DNA synthesis and mitosis, respectively (Figure 3) [111]. In addition, there is a fifth phase, referred to as G0 which represents a state of quiescence outside the cell cycle in which cells are not actively dividing or preparing to divide. Control of the cell cycle is accomplished via the coordinated interaction of cyclins with their respective cyclin-dependant kinases (CDKs) to form active complexes and drive cells into the next phase at the appropriate time. Regulatory checkpoint control is mediated by the tumor suppressor gene p53 and serves to monitor the accuracy of vital events such as DNA replication and chromosome


segregation, and can result in halting of the cell cycle to allow for repair if delinquencies are detected [112].

Specific cyclin/CDK complexes regulate various points in the cycle and are themselves substrates for other regulatory molecules with the most regulated points being the G1/S and G2/M transitions. Cyclin D family of proteins complex with CDK4 and CDK6 and promote progression through G1, Cyclin E/CDK2 complex promotes entry into S phase, Cyclin A/CDK2 stimulates G2 progression, and Cyclin B/CDK1 activates entry into the mitotic phase [113].

There are two distinct families of CDK inhibitors: the INK-4 family (p15^{Ink4b}, p16^{Ink4a}, p18^{Ink4c}, p19^{Ink4d}) and the Cip/Kip family (p21^{Cip1/Waf1}, p27^{Kip1}, p57^{Kip2}). The INK4 family of inhibitors binds to CDK4 and CDK 6 to prevent their association with Cyclin D, while the Cip/Kip family binds both CDKs and cyclins to inhibit the formation of the various cyclin/CDK complexes [114,115]. At the G1/S transition, the Cyclin D/CDK4,6 complexes promote progression by phosphorylating the pRB protein, releasing the transcription factor E2F and freeing it to transcribe genes required for cell division [116,117]. Curcumin has been shown to upregulate the expression of the Cip/Kip family of CDK inhibitors (p21^{Cip1/Waf1} and p27^{Kip1}), thus inhibiting the association of cyclin D1 with CDK4,6 [118]. In addition, decreased phosphorylation of Rb and suppressed transcription of E2F-regulated genes in the presence of curcumin has been demonstrated [119].

Derangements in the regulatory control of the cell cycle can result in the formation of tumor cells, in which growth and proliferation proceeds unchecked. One such example is overexpression of cyclin D1, which has been observed in many types of cancer including hematologic malignancies and various solid tumors [120,121]. Curcumin has been shown to suppress the expression of cyclin D1 in many types of cancer including head and neck, colon, bladder, breast, cervical and pancreatic carcinomas, an effect attributed to curcumin's inhibition of NF-κB activation and subsequent suppression of downstream gene products [48,53,108,109,122-124].

There are two main apoptotic pathways: the intrinsic (mitochondrial) pathway and the extrinsic (death receptor) pathway. The intrinsic pathway involves p53 functioning as a transcription factor to upregulate the expression of Bax (Figure 4). Bax is a pro-apoptotic protein that antagonizes Bcl-2, an anti-apoptotic protein that is present in the mitochondrial membrane [125]. When the Bax/Bcl-2 ratio is increased, the protective effect of Bcl-2 on the mitochondrial membrane is disrupted and permeability increases, allowing cytochrome c to leak into the cytosol. Cytochrome c binds to Apaf-1 (apoptotic protease activating factor-1) to form an apoptosome complex, which initiates the caspase cascade via






Figure 4 Programmed cell death type I: Apoptosis: In response to cellular damage, activation of p53 results in increased expression of Bax and antagonism of the anti-apoptotic protein Bcl-2. As a result, mitochondrial membrane permeability increases and cytochrome C is released into the cytosol. Cytochrome C binds Apaf-1 to form an apoptosome complex leading to activation of caspase-9 and initiation of the caspase cascade and resultant cell death.

activation of caspase-9 and results in cell death via enzymatic destruction of cytoplasmic proteins and DNA [126]. Curcumin has been shown to selectively induce apoptosis in tumor cells at the G2 phase via upregulation of p53 expression and initiation of the mitochondrial apoptotic pathway via increased Bax expression and cytochrome c release [125-129].

Curcumin also has a stimulatory effect on the extrinsic apoptotic pathway, which is triggered by the binding of “death activators” such as TNF- α , and Fas Ligand to their corresponding cell surface receptors. Activation of these receptors results in activation of caspase-8 via the receptor-attached FADD adapter molecule and initiation of the caspase cascade [130,131]. Curcumin has been shown to increase the levels of Fas and FADD and induce apoptosis in mouse-rat retinal ganglion cells [131]. A study in melanoma demonstrated that curcumin led to apoptosis by promoting aggregation of Fas receptors and by increasing levels of caspase-8 and -3 without altering the level of caspase-9 (unique to the intrinsic pathway) [132]. In addition, curcumin’s suppression of the NF- κ B mediated cell survival pathway is also important in the compound’s pro-apoptotic effect [132-134].

Effects on Autophagic Cell Death

Autophagy is a catabolic process in which cells break down their own components via engulfment in vacuoles and degradation through the lysosomal system (Figure 5). The hallmark of autophagy is thus the formation of these so-called “autophagosomes”, double layered




Figure 5 Programmed cell death type II: Autophagy is a catabolic process by which cells degrade their own components via the lysosomal system. In response to cellular or nutrient stress, double-layered autophagosomes containing cytoplasmic proteins and organelles are formed following envelopment by a membrane derived from the endoplasmic reticulum. Upon fusion with lysosomes, the contents of these autophagolysosomes are degraded. Autophagy is important as a housekeeping function to promote cell survival and may also function as a pathway of programmed cell death.

vacuoles which contain cytoplasmic proteins and organelles targeted for degradation upon fusion with the lysosome [135]. Autophagy is a housekeeping process by which cells may dispose of old or damaged cytoplasmic organelles and proteins, and also serves an adaptive function under conditions of nutrient stress by allowing cells to recycle endogenous biosynthetic substrates such as amino acids.¹³³ In addition to promoting cell survival and function, autophagy is also a method by which cells may undergo programmed cell death [136]. Autophagy is considered Type II programmed cell death (apoptosis is type I and necrosis is type III) and, thus has come under interest as a potential process that may be exploited in the development of anti-cancer chemotherapeutics.

The possible roles of autophagy in carcinogenesis as well as tumor regression in response to therapy are still being elucidated, with seemingly conflicting studies suggesting that induction of autophagy enhances cell death in certain tumor types while mediating chemotherapeutic resistance in others. On one hand, there is evidence that autophagy may be employed by cancer cells to facilitate growth under the stressful metabolic conditions commonly encountered in the tumor microenvironment (such as hypoxia and decreased availability of glucose and other nutrients due to poor vascularization) [137-139]. In addition, the induction of autophagy as an adaptive response mediating resistance to chemotherapy

has been observed in multiple tumor types including malignant gliomas, lymphoma, breast, lung and hepatocellular carcinomas [140-146].

On the other hand, there is genomic evidence that disruption of autophagy is associated with tumorigenesis, as suggested by the mono-allelic deletion of the autophagy-related gene beclin-1 in a high percentage of breast and ovarian cancers [147]. Studies in mice have demonstrated that monoallelic deletion of beclin-1 increases the frequency of spontaneous malignancies including hepatocellular carcinoma, B cell lymphoma and lung adenocarcinomas in beclin-1 +/- mice, suggesting beclin-1 as a haploinsufficient tumor suppressor gene [148]. In addition it was found that monoallelic deletion of beclin-1 resulted in increased cellular proliferation, decreased autophagy as measured by expression of the autophagosome membrane protein LC3, and accelerated the development of hepatitis B-induced premalignant lesions [149]. Conversely, transfection of beclin-1 into MCF-7 breast cancer cells (which express a very low baseline level of the protein) inhibited the cellular proliferation and tumorigenicity in a nude mouse xenograft model [147].

While autophagy appears to play a role in mediating chemoresistance in certain cancers as described above, there is also data supporting that autophagy may also induce non-apoptotic cell death in response to chemotherapy. In human (MCF-7) estrogen-receptor positive breast cancer, both tamoxifen and paclitaxel were found to induce autophagic cell death in cell culture [150,151]. Arsenic trioxide was found to induce autophagic cell death in malignant glioma, leukemia and fibrosarcoma cells, and in leukemia this effect was accompanied by up-regulation of beclin-1 [152-154]. The small molecule tyrosine kinase inhibitor imatinib has been shown to induce cellular autophagy, an effect that may sensitize drug-resistant Kaposi sarcoma cells [155,156]. Interestingly, imatinib's induction of autophagy seems to decrease its effectiveness in chronic myelogenous leukemia (CML) and blocking of autophagy lead to increased apoptotic cell death [142]. Studies done in malignant glioma cells have also yielded varying results; while autophagy induced by arsenic trioxide resulted in increased cell death, treatment with temolozamide and etoposide led to an increase in ATP that exerted a protective effect [152,157]. Likewise, there is controversy regarding the effect of autophagy induction on radiation sensitivity. Studies in breast cancer have suggested that vitamin D-dependant radiosensitization is mediated through autophagy, while autophagy has demonstrated both radiosensitizing and dampening effects in malignant gliomas [158-160].

Curcumin has been shown to be an inducer of autophagic cell death in chronic myelogenous leukemia,

esophageal cancer and malignant glioma cells [161-163]. In malignant glioma cells, curcumin induced G2/M cell cycle arrest and non-apoptotic autophagic death. This effect was mediated through curcumin's inhibition of the Akt/mTOR/p70S6 kinase pathway and inhibition of the ERK1/2 pathway, which are both involved in the regulation of autophagy induced by nutrient stress. In addition, these effects were confirmed via activation of the Akt/mTOR/p70S6 pathway which decreased curcumin-induced autophagic cell death as well as activation of the ERK1/2 pathway, which resulted in inhibition of autophagy and induction of apoptosis [163,164]. While the current data on autophagy and cancer is far from providing a consensus, it is evident that regulation of this process may play an important role in tumorigenesis and response to therapy thus making pharmacologic modulators of autophagy attractive candidates for further study.

Effects on Angiogenesis and Metastasis

The stimulation of new blood vessel growth is an essential step for tumor growth and metastasis in order to provide for the metabolic needs of rapidly proliferating malignant cells. Angiogenesis is regulated by a variety of pro-angiogenic genes and signaling molecules including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), platelet-derived growth factors, hypoxia-inducible factors, angiopoietin-1 and 2, and matrix metalloproteinases [165]. The role of angiogenesis in tumor growth has been targeted by newer chemotherapeutic agents such as bevacizumab, an anti-VEGF monoclonal antibody that is FDA approved for metastatic forms of various cancers including colon, non-small cell lung, HER2-negative breast cancer and renal cell carcinoma. In addition to bevacizumab, sorafenib and sunitinib are novel small-molecule inhibitors of multiple receptor tyrosine kinase (RTK) pathways involved in signal transduction from angiogenic receptors such as VEGFR and PDGF-R that are approved for renal cell carcinoma as well as hepatocellular carcinoma and gastrointestinal stromal tumor, respectively [166]. Curcumin has demonstrated an anti-angiogenic effect in vivo in xenograft models of various tumors including glioblastoma, hepatocellular carcinoma, prostate and ovarian carcinomas [134,167-169]. Curcumin has been shown to regulate a variety of pro-angiogenic growth factors, enzymes and transcription factors including bFGF, VEGF, angiopoietin-1 and 2, COX-2, matrix metalloproteinase-9 (MMP-9), AP-1 and NF- κ B [170-172]. Curcumin has also been shown to inhibit the angiogenic response to FGF-2 stimulation in mouse endothelial cells and decrease the expression of MMP-9, an enzyme involved in tissue remodeling that is important for the growth of new blood vessels [171]. In addition, curcumin treatment decreased the levels of the

angiogenic biomarkers COX-2 and VEGF in hepatocellular carcinoma cells, and resulted in a reduction in tumor neocapillary density compared to the untreated cells [172].

In addition to its inhibitory effects on angiogenesis, curcumin has also been demonstrated to affect a number of cellular adhesion molecules involved in the processes of tumor growth and metastasis. A study of curcumin in metastatic melanoma demonstrated a dose dependant reduction in binding to extracellular matrix proteins, decreased expression of alpha5beta1 and alpha(v)beta3 integrin receptors and increased expression of various anti-metastatic proteins including tissue inhibitor metalloproteinase (TIMP-2), nonmetastatic gene 23 (Nm23) and E-cadherin [173]. E-cadherin expression is important in maintaining the integrity of intercellular adhesion through binding to various catenins (including β -catenin), and loss of E-cadherin is associated with an increased tendency for tumor metastasis [174]. Anti-metastatic effects of curcumin have also been demonstrated in the MDA-MB-231 breast cancer cell line, resulting in decreased expression of matrix metalloproteinases, ICAM-1 and chemokine receptor 4 (CXCR4) and suppressed cell migration and invasion [175]. In addition, curcumin was shown to decrease the ability of paclitaxel-resistant breast cancer cells to form lung metastases via suppression of various anti-apoptotic proteins (including XIAP, Bcl-2 and IAP1 and 2), proliferative (COX-2, c-myc and cyclin D1), and metastatic proteins (MMP-9, VEGF and ICAM-1) [176]. As many pro-angiogenic and pro-metastatic genes are regulated by NF- κ B (including COX-2, VEGF, ICAM-1 and MMP-9 among others), curcumin's suppressive effect on NF- κ B activation likely plays a key role in mediating the compound's anti-angiogenic and anti-tumorigenic effects.

Therapeutic Activity of Curcumin in Head and Neck Squamous Cell Carcinoma

Curcumin has been studied in various in vitro and vivo models of head and neck squamous cell carcinoma with promising results. An overview of current literature supporting the spice's utility in the treatment of head and neck cancer including as a chemopreventive agent, as well as future directions for study is presented below.

In Vitro Studies

Studies of curcumin in various head and neck cancer cell lines have demonstrated decreased cell growth and survival, concomitant with the compound's effects on molecular pathways involved in cellular proliferation. Expression of constitutively active NF- κ B and I κ K has been observed in multiple oral squamous cell carcinoma cell lines, and curcumin treatment was shown to suppress growth and survival of these cell lines via inhibition of NF- κ B activation [43]. Signal-transducer-and-

activator-of-transcription-3 (STAT3) is a signaling protein observed to be overexpressed in multiple head and neck cancers, and curcumin was shown to suppress the IL-6 mediated phosphorylation of STAT3 as well as inhibiting nuclear localization [177]. In another study, Chakravarti et al [178] demonstrated that curcumin suppressed the growth of immortalized oral mucosal epithelial cells and squamous cell carcinoma cells (UMSCC22B and SCC4) while having minimal effect on normal oral epithelial cells. Curcumin was shown to reduce the efficiency of the eIF4F translational complex of these immortalized cells via suppression of phosphorylation of 4E-BP1, eIF4G, eIF4B and Mnk1, as well as a reduction in the total levels of eIF4E and Mnk1. In SAS oral cancer cells, curcumin induced the promoter activity of insulin-like growth factor binding protein-5 (IGFBP-5) and CCAAT/enhancer-binding protein alpha (C/EBPalpha), proteins involved in the suppression of head and neck cancers. The inhibitory effects of curcumin on IGFBP-5 and C/EBP-alpha were mediated via p38 activation, and resulted in decreased in vivo tumorigenesis in a mouse xenograft model [179].

Our laboratory has studied the effects of curcumin in several head and neck squamous cell carcinoma cell lines: CCL23 (laryngeal), CAL27, UM-SCC14A and UM-SCC1 (oral) [48,53,180]. The growth suppressive effect was shown to be mainly mediated via the effects of curcumin on the NF- κ B pathway. Curcumin was shown to decrease the expression of NF- κ B and also inhibited its nuclear localization; this observation was supported by a concomitant decrease in phospho-I κ B- α expression [46]. In addition, the expression levels of multiple NF- κ B regulated gene products (including cyclin D1, MMP-9, COX-2, Bcl-2, Bcl-xL, IL-6, IL-8, Mcl-1L and Mcl-1S) were reduced [48,53].

It has been demonstrated that the curcumin-induced suppression of the NF- κ B pathway in head and neck cancer cells is due to inhibition of I κ K (inhibitor kappa B kinase), thus blocking the phosphorylation of I κ B- α and resulting in NF- κ B sequestration in the cytoplasm. We have shown dose-dependent suppression of IL-6 and IL-8 following curcumin treatment in CCL23, CAL27, UM-SCC1 and UM-SCC14A cell lines via inhibition of I κ K activity [178]. Furthermore, the curcumin-induced inhibition of I κ K was found to take place via an AKT-independent mechanism [53]. The data on curcumin's effect on the AKT pathway is varying; while it has been shown to act independently of AKT in HNSCC as well as melanoma, curcumin suppresses the AKT pathway in other tumors such as malignant gliomas and pancreatic cancer [96,163,181]. AKT (another kinase of transcription, also known as protein kinase B) is a protein kinase involved in signal transduction from oncogenes and growth factors. The AKT signaling cascade is

stimulated by EGFR, and represents one pathway by which NF- κ B may be activated [182]. As discussed earlier, EGFR is overexpressed in many head and neck cancers and molecular therapies targeting the EGFR/AKT signaling cascade (such as cetuximab) have been shown to increase the therapeutic efficacy of standard platinum-based chemotherapy [16,17]. The finding that curcumin suppresses NF- κ B independently of the AKT pathway in HNSCC is of clinical significance, as it acts via a different mechanism than cetuximab and the two agents could potentially be used in combination for treating head and neck cancers.

In vivo studies

Curcumin has demonstrated *in vivo* growth suppressive effects on head and neck squamous cell carcinoma using nude mouse xenograft models. The lipophilic nature of curcumin and relative insolubility in aqueous solutions, combined with short half life and low bioavailability following oral administration has presented a significant challenge in developing an effective delivery system for its use as a chemotherapeutic agent [183]. In an effort to overcome this obstacle, various strategies are being tried including the use of piperine as an adjuvant agent to slow curcumin breakdown as well as the development of liposomal, phospholipid and nanoparticulated formulations of the compound to enable intravenous administration [183]. Liposomal formulations of curcumin have been studied in various cancers including pancreatic, colorectal and prostate [184-186].

Intravenous liposomal curcumin has been studied by our laboratory in mouse xenograft tumors of the oral cancer cell lines CAL27 and UM-SCC-1, and was found to be both nontoxic as well as effective at suppressing tumor growth. Xenograft mouse tumors were stratified into groups receiving no treatment, treatment with empty liposomes or treatment with liposome encapsulated curcumin and a statistically significant growth suppressive effect was observed in the liposomal curcumin group [53]. The presence of curcumin in mouse serum and liver was confirmed using liquid chromatography-mass spectrophotometry, demonstrating increased systemic absorption of liposomal curcumin relative to a DMSO-suspension of curcumin. Immunohistochemistry of the tumor samples revealed decreased expression of NF- κ B in the liposomal curcumin-treated tumors relative to both the liposomal control and untreated groups, while the staining intensity of pAKT did not show a significant difference among the three treatment groups, further supporting the *in vitro* findings that curcumin's growth suppressive effects are related to the suppression of NF- κ B in an AKT-independent manner [53].

A recent study by Clark et al [187] has shown chemopreventive effects of curcumin in mouse xenograft

models of oral squamous cell carcinoma. These authors have demonstrated an inhibitory effect on tumor growth following treatment of the mice with an oral curcumin solution both prior to inoculation of SCC40 tongue squamous cell carcinoma cells as well as when curcumin was initiated after tumor formation. In addition, curcumin oral solution was studied in a mouse model of oral carcinogenesis in which the tobacco derivative 4-nitroquinolone-1-oxide was painted inside the animal's mouths several times weekly, with or without concurrent oral curcumin solution. In the mice receiving concurrent curcumin, tumor-free and overall survival times were significantly increased. Here, the effects of curcumin on carcinogenesis suppression were found to be mediated via inhibition of the AKT/mTOR pathway following analysis of treated and untreated tumor cell extracts. Finally, curcumin was found to decrease migration and invasion of malignant oral squamous cells via a downregulation in MMP-9 expression.

Curcumin as an adjuvant therapy

While studies of curcumin as a single agent in the treatment of head and neck cancer have shown promising results, there is significant interest in potentially using the compound as an adjuvant agent in combination with standard platinum-based chemotherapy for the treatment of head and neck tumors. Data from our laboratory in both CAL27 and UMSCC-1 cell lines demonstrated an increased growth suppressive effect in cells treated with a combination of liposomal curcumin and cisplatin, both *in vitro* as well as in mouse xenograft tumor models [188]. While treatment with either curcumin or cisplatin *in vitro* resulted in cell death, a combination of curcumin and suboptimal concentrations of cisplatin demonstrated a significant growth suppressive effect compared to treatment with either agent alone. Curcumin's suppressive effect was again shown to derive from the inhibition of cytoplasmic and nuclear I κ K, leading to inhibition of NF- κ B activity. There was no effect on pAKT, supporting an AKT-independent mechanism for NF- κ B inhibition. Cisplatin treatment led to cellular senescence, an effect mediated through increased expression of p16 and p53 [7]. Differing mechanisms of curcumin and cisplatin suggest potential for the clinical use of subtherapeutic doses of cisplatin in combination with curcumin to accomplish effective suppression of tumor growth while minimizing cisplatin's toxic side effects.

In addition to the potential synergistic effect of curcumin with platinum based chemotherapy, the spice may also have potential utility as an enhancer of radiation therapy. A recent study by Khafif et al [189] compared the effects of curcumin and single-dose radiation alone and in combination in the HNSCC cell lines SCC-1, SCC-9, A431 and KB. *In vitro* growth suppression with

either curcumin or radiation was observed in all four cell lines, and the combination of both therapies resulted in an additive growth suppressive effect. Curcumin was found to arrest carcinoma cells in the G2/M phase of the cell cycle, in which cells are more susceptible to the cytotoxic effects of radiotherapy. In addition, curcumin was shown to decrease COX-2 expression and inhibit EGFR phosphorylation in SCC-1 cells. In vivo experiments using orthotopic mouse models of SCC-1 tumors also supported the additive effects of curcumin and radiation therapy. While curcumin has exhibited varying effects on radiation sensitivity in different cancer cell types, its effect as a radiosensitizer has been supported in several other tumors in addition to HNSCC including prostate, colorectal and ovarian cancers [190-193].

Future Directions of Study for Curcumin in HNSCC

As discussed in this review, curcumin has demonstrated powerful anti-cancer effects in a variety of malignancies via its effects on a host of biological pathways involved in tumorigenesis and cellular growth. Continuing investigation into the molecular pathways affected by curcumin is indicated to further define the effects of the compound on growth signaling pathways, apoptotic and non-apoptotic cell death, oncogene and tumor suppressor regulation. Translating this abundance of molecular data into eventual clinical applications is a paramount goal of future research. In head and neck cancers, a promising area of study centers around the use of curcumin to treat platinum-refractory tumors, which are associated with a poorer prognosis and have a tendency for disease recurrence. Some work has been done in the area of characterizing putative 'cancer stem cells' in a variety of tumor types including HNSCC, breast, colorectal and prostate cancers [194-197]. Cancer stem cells are not true multipotent stem cells, but are a sub-population of highly tumorigenic cells that are theorized to contribute to chemoresistance and recurrence [198]. CD44 is a cell surface marker that has been shown to be highly expressed in putative head and neck cancer stem cells [196-200]. Our laboratory has demonstrated a population of CD44^{High} putative stem cells within the UM-SCC1 cell line that possess increased tumorigenicity, growth rate and resistance to cisplatin treatment relative to CD44^{Low} cells [201]. Investigating the growth suppressive properties of curcumin in these highly tumorigenic cells could be an initial study in quantifying the utility of the compound in chemotherapy-resistant head and neck cancers, and may have applications in other types of chemoresistant malignancies as well. The solubility of curcumin in an intravenous delivery system is a major consideration in formulating the compound as a suitable chemotherapeutic agent. While our laboratory and others have shown increased therapeutic

efficacy of liposomal curcumin, it is possible that other delivery systems may yield superior bioavailability and therapeutic results.

Other Biologic Therapies Currently Under Investigation in HNSCC

In addition to curcumin, multiple other biologically targeted agents are currently being studied in head and neck cancer. As previously mentioned EGFR is overexpressed in many head and neck cancers and therefore represents a promising potential therapeutic target. The anti-EGFR monoclonal antibody cetuximab is approved both in combination with radiotherapy as well as a single agent for platinum-resistant HNSCC, but is also being investigated in combination with standard chemotherapeutic regimens. A Phase I/II trial of cetuximab with 5-FU and either carboplatin or cisplatin showed increased survival without a significantly increased toxicity relative to the standard chemotherapy regimen (Table 1) [202]. However, acquired resistance to EGFR inhibition by cetuximab has emerged as a therapeutic challenge [203]. A variant of EGFR (EGFRvIII) that results in constitutive activation of the downstream Ras/Raf/MAPK, STAT3 and PI3/AKT/mTOR pathways has been observed in HNSCC that is not responsive to EGFR inhibition [204]. In addition to targeting the extracellular EGF receptor, tyrosine kinase inhibitors (erlotinib, gefitinib, lapatinib) that block intracellular EGFR phosphorylation and inhibit downstream signal transduction are also being studied in HNSCC. A Phase II study of erlotinib in patients with recurrent or metastatic head and neck cancer showed an increase in disease stabilization (Table 2) [205]. A Phase III trial of gefitinib alone compared to methotrexate monotherapy in recurrent HNSCC failed to show a significant survival increase, but a more recent study of gefitinib added to concurrent chemoradiation showed a favorable response that correlated to the number of EGFR copies in the various tumors [206,207].

Targeted therapies against the vascular endothelial growth factor receptor (VEGF) are also being evaluated in HNSCC. The anti-VEGF monoclonal antibody bevacizumab in combination with paclitaxel showed increased anti-tumor effects in mouse xenograft tumor models of HNSCC compared to either agent alone [208]. A combination of bevacizumab and erlotinib was also studied in a Phase I/II clinical trial in recurrent or metastatic HNSCC and demonstrated a response rate of 15%, which was significantly increased compared to prior studies of erlotinib (5%) or single agent anti-angiogenic therapies (4%) [209].

Constitutive activation of the PI3-K/Akt/mTOR pathway has been observed in head and neck cancer and is associated with resistance of such tumors to radiation and chemotherapy [210]. As such employing rapamycin

Table 2 Current molecular pathway based therapies in head and neck cancer

Agent	Molecular target	Phase/model of investigation in HNSCC	Reference
Erlotinib/ Gefitinib/ Lapatinib	Anti-EGFR receptor kinase	Erlotinib: Phase II study in refractory/metastatic HNSCC Gefatinib: PhaseIII vs methotraxate in recurrent HNSCC	[205-207]
Bevacizumab	Anti-VEGF monoclonal antibody	Mouse xenograft models: in combination with paclitaxel Phase I/II trial of bevacizumab and erlotinib in recurrent/metastatic HNSCC	[208]
Rapamycin derivatives (Everolimus, Deferolimus, Temserolimus)	Inhibition of PI3K/AKT/mTOR pathway	Mouse xenograft model: Single agent CCI-779 in minimal residual disease Mouse xenograft model: CCI-779 in combination with radiotherapy	[210-212]
Sorafenib	Multikinase inhibitor targeting MAP kinase, VEGFR, PDGFR, FLT3, Ret, c-kit	Phase II: in chemotherapy-naïve persistent/recurrent HNSCC	[213,214]
Pemetrexed	Folate antimetabolite	Phase I: in combination with cisplatin in HNSCC Phase II: Pemetrexed plus gemcitabine in recurrent/metastatic HNSCC	[215,216]
Bortezomib	Proteasome inhibitor	Phase I: Bortezomib with re-irradiation in HNSCC Phase II: Bortezomib with docetaxel in recurrent/metastatic HNSCC in vitro: Synergistic anti-tumor effect of Bortezomib and cisplatin in HNSCC cell lines	[217-219]
Curcumin	Inhibition of NF-κB activation, Suppression of interleukins, Cell cycle inhibition, Suppression of VEGF and other angiogenic factors, Up-regulation of cellular adhesion molecules, inhibition of STAT 3	in vitro: Growth suppression of HNSCC cell lines with decreased NF-κB activation in vitro: Suppression of IL-6 and IL-8 expression in HNSCC in vitro: Growth suppression of immortalized epithelial cells Mouse xenograft: Suppression of CAL 27 cell line tumors Mouse model: Inhibition of oral carcinogenesis in vitro and mouse model: Synergistic anti-tumor effect of Curcumin and cisplatin in CAL 27 and UM-SCC1 cell lines in vitro and mouse model: Radiosensitization of SCC-1, SCC-9, A431, and KB HNSCC cell lines with curcumin	[48,53] [180] [178,187] [48,53] [178,187] [188] [189,190]

derivatives such as everolimus, deforolimus and temserolimus may prove useful in the treatment of refractory head and neck cancers. The experimental mTOR inhibitor CCI-779 has been studied as a single agent in mouse models of HNSCC minimal residual disease and demonstrated a significant increase in the tumor-free rate between the treatment and control groups (50% vs. 4% respectively) as well as a reduction in tumor volume in the CCI-779 group [211]. Analysis of the radiosensitizing effect of CCI-779 in mouse xenograft models of both cisplatin sensitive (FaDu) and resistant (SCC40) head and neck squamous cell carcinoma showed increased survival relative to radiotherapy alone. In addition, the antitumor effects of CCI-779 plus radiotherapy were superior when compared to conventional chemoradiotherapy with cisplatin in both the FaDu and SCC40 xenograft tumors [212].

In addition to the major pathways discussed above, several other novel biologic agents are under investigation in head and neck cancer that merit brief mention. Sorafenib is a multikinase inhibitor targeting the MAP kinase pathway (RAF/MEK/ERK) as well as several other receptor tyrosine kinases including VEGFR, PDGFR, FLT3, Ret and c-kit [213]. It is currently FDA approved for treatment of advanced primary renal cell carcinoma and hepatocellular carcinoma. A Phase II trial of sorafenib in chemotherapy-naïve persistent or recurrent HNSCC showed a relatively poor response rate of 2%, but progression-free and overall survival compared favorably with other single agent Phase II trials [214]. Pemetrexed is a folate antimetabolite currently FDA approved in combination with cisplatin for malignant mesothelioma. A Phase I study of pemetrexed in combination with cisplatin for HNSCC showed no enhancement in

cisplatin-related toxicities or alteration of the cisplatin pharmacokinetics [215]. A Phase II trial of pemetrexed plus gemcitabine in recurrent or metastatic HNSCC demonstrated a partial response rate of 16% and was well-tolerated [216]. Bortezomib is a proteasome inhibitor that is FDA approved for the treatment of multiple myeloma and mantle cell lymphoma. The cytoplasmic to nuclear translocation and activation of NF- κ B is a proteasome-dependant process, and bortezomib has been shown to inhibit nuclear activation of the RelA and NF- κ B1 subunits in HNSCC [217]. In addition bortezomib has been found to induce apoptosis in HNSCC cells via up-regulation of the pro-apoptotic proteins Bik and Bim, and the combination of bortezomib and cisplatin resulted in a synergistic tumoricidal effect in HNSCC [218]. A Phase II trial of bortezomib in combination with docetaxel in recurrent and/or metastatic HNSCC was well-tolerated and demonstrated better therapeutic response in tumors expressing lower levels of NF- κ B associated genes [219].

Conclusions

The need for alternative and less toxic therapies for head and neck squamous cell carcinoma is clear. Multiple molecular pathways such as NF- κ B activation, EGFR and PI3/AKT/mTOR signaling, STAT3 expression, the MAP kinase cascade and VEGF-mediated angiogenesis have been shown to be deregulated in HNSCC and represent potential therapeutic targets. While some promising results from such targeted therapies have been obtained, the complexity of interaction between these signaling pathways may contribute to the limited clinical response seen with the use of single-agent biologic therapies. As a natural product, curcumin is both non-toxic as well as diversified in its inhibitory effects on a multitude of pathways involved in carcinogenesis and tumor formation. While the compound alone has shown some anti-tumor effects in HNSCC, curcumin's lack of systemic toxicity and broad-reaching mechanism of action may make it best suited as an adjuvant therapy for head and neck cancers that are resistant to currently available therapies.

Credit

Permission is granted for the use of figure 3 from Arch. Otolaryngology Head and Neck Surgery 2006, **132**: 317-326 "Copyright (2006) American Medical Association, All rights reserved."

Acknowledgements

We thank Eugene Han for help with figures. The study was supported by funds from VAGLAHS, West Los Angeles Surgical Education Research Center, NIH (R21 CA116826-01 to M.B. Wang) and Merit grant from the Veterans Administration, Washington, DC (E.S. Srivatsan).

Author details

¹Department of Surgery, VA Greater Los Angeles Healthcare System, West Los Angeles, CA, USA. ²Division of Head and Neck Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. ³Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Authors' contributions

RW carried out literature survey and in association with MSV contributed to the design and draft of the manuscript. MBW participated in the design and coordination of the manuscript. ESS conceived of the study, and participated in the design and drafting of the manuscript. RW and ESS were also involved in the design of the figures. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 4 August 2010 Accepted: 7 February 2011

Published: 7 February 2011

References

1. Stell PM: Survival time in end-stage head and neck cancer. *Eur J Surgical Oncol* 1989, **15**:407-410.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer. *N Engl J Med* 1993, **328**:184-194.
3. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlander N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK: *SEER Cancer Statistics Review 1975-2007*. National Cancer Institute. Bethesda, MD .
4. Syrjänen S: The role of human papillomavirus infection in head and neck cancers. *Ann Oncol* 2010, **Suppl 7**:vii243-vii245.
5. Posner MR: Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. *Ann Oncol* 2010, **Suppl 7**:vii246-vii251.
6. Wong SJ, Harari PM, Garden AS, Schwartz M, Bellm L, Chen A, Curran WJ, Murphy BA, Ang KK: Longitudinal oncology registry of head and neck carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. *Cancer* 2010.
7. Yip H, Chopra R, Chakrabarti R, Veena MS, Ramamurthy B, Srivatsan ES, Wang MB: Cisplatin-induced growth arrest of head and neck cancer correlates with increased expression of p16 and p53. *Arch Otolaryngology Head and Neck Surgery* 2006, **132**:317-326.
8. Cohen EE, Lingen MW, Vokes EE: The expanding role of systemic therapy in head and neck cancer. *J Clin Oncol* 2004, **22**:1743-1752.
9. Chandana SR, Conley BA: Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects. *Curr Opin Oncol* 2009, **21**:218-223.
10. Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). *Head Neck* 2010, **32**:221-228.
11. Vissink A, Jansma J, Spigkervet FKL, Spijkervet FK, Burlage FR, Coppes RP: Oral sequelae of head and neck radiotherapy. *Crit Rev Oral Biol Med* 2003, **14**:199-212.
12. Thorn JJ, Hansen HS, Spetch L, Bastholt L: Osteoradionecrosis of the jaws: clinical characteristics and relation to field of irradiation. *J Oral Maxillofac Surg* 2000, **58**:1088-1093.
13. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE: Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. *Clin Cancer Res* 2004, **10**:1956-1962.
14. Bonner JA, Harai PM, Giral J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Yousoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. *N Engl J Med* 2006, **354**:567-578.
15. Bonner JA, Harai PM, Giral J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Yousoufian H, Rowinsky EK, Ang KK: Radiotherapy plus

- cetuximab for locoregionally advanced head and neck cancer: 5 year survival data from a phase 3 randomised trial and relation between cetuximab-induced rash and survival. *Lancet Oncol* 2010, **11**:21-8.
16. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: **Platinum based chemotherapy plus cetuximab in head and neck cancer.** *N Engl J Med* 2008, **359**:1116-1127.
 17. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J: **Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.** *Cancer* 2008, **112**:2710-2719.
 18. Chattopadhyay I, Biswas K, Bandyopadhyay U, Banerjee RK: **Turmeric and curcumin: Biological actions and medicinal applications.** *Curr Sci* 2004, **87**:44-50.
 19. Jurenka JS: **Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: A review of preclinical and clinical research.** *Altern Med Rev* 2009, **14**:141-153.
 20. Aggarwal BB, Sundaram C, Malani N, Ichikawa H: **Curcumin: The Indian solid gold.** *Adv Exp Med Biol* 2007, **595**:1-75.
 21. Ammon HP, Wahl MA: **Pharmacology of *Curcuma longa*.** *Planta Med* 1991, **57**:1-7.
 22. Aggarwal BB, Kumar A, Bharti AC: **Anticancer potential of curcumin: preclinical and clinical studies.** *Anticancer Res* 2003, **23**:363-398.
 23. Sreejayan Rao MN: **Curcuminoids as potent inhibitors of lipid peroxidation.** *J Pharm Pharmacol* 1994, **46**:1013-1016.
 24. Masuda T, Maekawa T, Hidaka K, Bando H, Takeda Y, Yamaguchi H: **Chemical studies on antioxidant mechanisms of curcumin: analysis of oxidative coupling products from curcumin and linoleate.** *J Agric Food Chem* 2001, **49**:2539-2547.
 25. Joe B, Vijaykumar M, Lokesh BR: **Biological properties of curcumin—cellular and molecular mechanisms of action.** *Crit Rev Food Sci Nut* 2004, **44**:97-111.
 26. Joe B, Lokesh BR: **Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages.** *Biochem Biophys Acta* 1994, **1224**:255-263.
 27. Brouet I, Ohshima H: **Curcumin, an anti-tumour and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages.** *Biochem Biophys Res Commun* 1995, **206**:533-540.
 28. Chan MM, Huang HI, Fenton MR, Fong D: **In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties.** *Biochem Pharmacol* 1998, **55**:1955-1962.
 29. Jung KK, Lee HS, Cho JY, Shin WC, Rhee MH, Kim TG, Kang JH, Kim SH, Hong S, Kang SY: **Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia.** *Life Sci* 2006, **79**:2022-2031.
 30. Ray B, Lahiri DK: **Neuroinflammation in Alzheimer's Disease: different molecular targets and potential therapeutic agents including curcumin.** *Curr Opin Pharmacol* 2009, **4**:434-444.
 31. He LF, Chen HJ, Qian LH: **Curcumin protects pre-oligodendrocytes from activated microglia in vitro and in vivo.** *Brain Res* 2010, **1339**:60-69.
 32. Chan MM: **Inhibition of tumor necrosis factor by curcumin, a phytochemical.** *Biochem Pharmacol* 1995, **49**:1551-1556.
 33. Singh S, Aggarwal BB: **Activation of transcription factor NF-kB is suppressed by curcumin (diferuloylmethane).** *J Biol Chem* 1995, **270**:24995-25000.
 34. Brennan P, O'Neill LA: **Inhibition of nuclear factor kappaB by direct modification in whole cells: Mechanism of action of nordihydroguaiaric acid, curcumin and thiol modifiers.** *Biochem Pharmacol* 1998, **55**:965-973.
 35. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB: **Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity.** *J Immunol* 1999, **163**:3474-3483.
 36. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L: **Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex.** *Oncogene* 1999, **18**:6013-6020.
 37. Chuang SE, Cheng AL, Lin JK, Kuo ML: **Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats.** *Food Chem Toxicol* 2000, **38**:991-995.
 38. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS: **Molecular mechanisms underlying chemoprotective activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.** *Mutation Res* 2001, **480-481**:243-268.
 39. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL: **Basal levels and patterns of anticancer drug-induced activation of nuclear factor kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells.** *Biochem Pharmacol* 2002, **63**:1709-1716.
 40. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS: **Curcumin downregulates AR gene expression and activation in prostate cancer cell lines.** *Int J Oncol* 2002, **21**:825-30.
 41. Han SS, Seo HJ, Surh YJ: **Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells.** *J Biochem Mol Biol* 2002, **35**:337-342.
 42. Bharti AC, Donato N, Singh S, Aggarwal BB: **Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and I-kappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.** *Blood* 2003, **101**:1053-1062.
 43. Chun KS, Keum YS, Han SS, Song YS, Kim SH, Surh YJ: **Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation.** *Carcinogenesis* 2003, **24**:1515-1524.
 44. Shishodia S, Potdar P, Gairola CG, Aggarwal BB: **Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of I-kappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1.** *Carcinogenesis* 2003, **24**:1269-1279.
 45. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB: **Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kB signaling.** *Int J Cancer* 2004, **111**:679-692.
 46. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE: **Curcumin suppresses the paclitaxel-induced nuclear factor kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.** *Clin Cancer Res* 2005, **11**:7490-7498.
 47. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M: **Effects of curcumin (diferuloylmethane) on nuclear factor kappa B signaling in interleukin-1beta-stimulated chondrocytes.** *Ann N Y Acad Sci* 2004, **1030**:578-586.
 48. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, Cohen AN, Chakrabarti R, Srivatsan ES, Wang MB: **Curcumin suppresses growth of head and neck squamous cell carcinoma.** *Clin Cancer Res* 2005, **11**:6994-7002.
 49. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N: **Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells.** *Int J Cancer* 2006, **118**:765-772.
 50. Marin YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J, Lee HJ, Rabson AB, Yang CS, Chen S, Ryu JH: **Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.** *Melanoma Res* 2007, **17**:274-283.
 51. Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Hohnke C, Jochum M, Nerlich AG, Pfeffer U: **Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NF-kappaB.** *Carcinogenesis* 2008, **29**:779-789.
 52. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS: **Curcumin inhibits NF-kappa B mediated radioprotection and modulates apoptosis related genes in human neuroblastoma cells.** *Cancer Biol Ther* 2008, **7**:569-576.
 53. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB: **Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.** *Clin Cancer Res* 2008, **14**:6228-6236.

54. Fiorillo C, Becatti M, Pensalfini A, Cecchi C, Lanzilao L, Donzelli G, Nassi N, Giannini L, Borchi E, Nassi P: **Curcumin protects cardiac cells against ischemia reperfusion injury: effects on oxidative stress, NF-kappaB and JNK pathways.** *Free Radic Biol Med* 2008, **45**:839-846.
55. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanius LC, Al-Kuraya KS, Uddin S: **Curcumin suppresses constitutive activation of nuclear-factor kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines.** *Mol Cancer Ther* 2008, **7**:3318-3329.
56. Kang HJ, Lee SH, Price JE, Kim LS: **Curcumin suppresses the paclitaxel-induced nuclear factor kappa B in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in breast cancer nude mice model.** *Breast J* 2009, **15**:223-9.
57. Panicker SR, Kartha CC: **Curcumin attenuates glucose-induced monocyte chemoattractant protein-1 synthesis in aortic endothelial cells by modulating the nuclear-factor kappaB pathway.** *Pharmacology* 2010, **85**:18-26.
58. Barnes PJ, Karin M: **Nuclear factor-kB, a pivotal transcription factor in chronic inflammatory diseases.** *N Engl J Med* 1997, **336**:1066-1071.
59. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: **De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.** *Nature* 2004, **430**:694-699.
60. Gilmore TD: **Introduction to NF-kB: players, pathways, perspectives.** *Oncogene* 2006, **25**:6680-6684.
61. Brasier AR: **The NF-kB regulatory network.** *Cardiovasc Toxicol* 2006, **6**:111-130.
62. Perkins ND: **Integrating cell-signalling pathways with NF-kB and IKK function.** *Nat Rev Mol Cell Biol* 2007, **8**:49-62.
63. Gilmore TD: **The Rel/NF-kB signal transduction pathway: introduction.** *Oncogene* 1999, **18**:6842-6844.
64. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB: **Cigarette smoke condensate activates nuclear transcription factor-kB through phosphorylation and degradation of IkB(a): correlation with induction of cyclooxygenase-2.** *Carcinogenesis* 2002, **23**:1511-1518.
65. Garg A, Aggarwal BB: **Nuclear transcription factor-kB as a target for cancer drug development.** *Leukemia* 2002, **16**:1053-1068.
66. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV, Mukaida N, Van Waes C: **Constitutive activation of transcription factors NF-(k)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines.** *Mol Carcinog* 1999, **26**:119-129.
67. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C: **Nuclear NFkappa-B p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer.** *Clin Cancer Res* 2009, **15**:5974-5984.
68. Ghosh S, Karin M: **Missing pieces of the NF-kB puzzle.** *Cell* 2002, **109**(Suppl):S81-96.
69. Abe Y, Hashimoto S, Horie T: **Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages.** *Pharmacol Res* 1999, **39**:41-47.
70. Rao CV: **Regulation of COX and LOX by curcumin.** *Adv Exp Med Biol* 2007, **595**:213-26.
71. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH: **Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis.** *Cancer Res* 1991, **51**:813-819.
72. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ: **Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells.** *Carcinogenesis* 1999, **20**:445-451.
73. Koerberle A, Northoff H, Werz O: **Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1.** *Mol Cancer Ther* 2009, **8**:2348-2355.
74. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: **The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.** *J Neurosci* 2001, **21**(21):8370-8377.
75. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kaye R, Glabe CG, Frautschy SA, Cole GM: **Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.** *J Biol Chem* 2005, **280**:5892-5901.
76. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraiishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y: **Curcumin as maintenance therapy for ulcerative colitis: randomized, multi-center, double-blind, placebo-controlled trial.** *Clin Gastroenterol Hepatol* 2006, **4**:1502-1506.
77. Yadav VR, Suresh S, Devi K, Yadav S: **Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease.** *J Pharm Pharmacol* 2009, **3**:311-321.
78. Yeh CH, Chen TP, Wu YC, Lin YM, Jing Lin P: **Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion.** *J Surg Res* 2005, **125**:109-116.
79. Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N: **Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation.** *Arterioscler Thromb Vasc Biol* 2006, **26**:85-90.
80. Babu PS, Srinivasan K: **Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in an albino rat.** *Mol Cell Biochem* 1995, **152**:13-21.
81. Meghana K, Sanjeev G, Ramesh B: **Curcumin prevents streptozoin-induced islet damage by scavenging free radicals: a prophylactic and protective role.** *Eur J Pharmacol* 2007, **577**:183-191.
82. Ram A, Das M, Ghosh B: **Curcumin attenuates allergen-induced airway hyperresponsiveness in sensitized guinea pigs.** *Biol Pharm Bull* 2003, **26**:1021-1024.
83. Moon DO, Kim MO, Lee HJ: **Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide.** *Biochem Biophys Res Commun* 2008, **375**:275-279.
84. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J: **Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis.** *J Biol Chem* 2000, **275**:444-450.
85. Mun SH, Kim HS, Kim JW, Ko NY: **Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: inhibition of the PKCdelta/JNK/C-Jun pathway.** *J Pharmacol Sci* 2009, **111**:13-21.
86. Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandolfi SJ: **Curcumin ameliorates ethanol and nonethanol experimental pancreatitis.** *Am J Physiol Gastrointest Liver Physiol* 2003, **284**:G85-95.
87. Durgaprasad S, Pai CG, Vasanthkumar Alvres JF, Namitha S: **A pilot study of the antioxidant effects of curcumin in tropical pancreatitis.** *Indian J Med Res* 2005, **122**:315-318.
88. Jones EA, Shoskes DA: **The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair.** *J Urol* 2000, **163**:999-1004.
89. Chiu J, Khan ZA, Farhangkhoei H: **Curcumin prevents diabetes associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB.** *Nutrition* 2009, **25**:964-972.
90. Aggarwal BB, Harikumar KB: **Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.** *Int J Biochem Cell Biol* 2009, **41**:40-59.
91. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB: **Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines.** *Oncogene* 2001, **20**:7597-7609.
92. Mehta K, Pantazis P, McQueen T, Aggarwal BB: **Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines.** *Anticancer Drugs* 1997, **8**:470-481.
93. Hanif R, Qiao L, Schiff SJ, Rigas B: **Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway.** *J Lab Clin Med* 1997, **130**:576-584.
94. Elattar TM, Virji AS: **The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in-vitro.** *Anticancer Res* 2000, **20**:1733-1738.
95. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK: **Curcumin inhibits tumor growth and angiogenesis in ovarian**

- carcinoma by targeting the nuclear factor-kappaB pathway. *Clin Cancer Res* 2007, **13**:3423-3430.
96. Siwak DR, Shishodia S, Aggarwal BB, Kuzrock R: Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. *Cancer* 2005, **104**:879-890.
97. Mohandas KM, Desai DC: Epidemiology of digestive tract cancers in India. V. Large and small bowel. *Indian J Gastroenterol* 1999, **18**:118-121.
98. Oda Y: Inhibitory effect of curcumin on SOS functions induced by UV irradiation. *Mutat Res* 1995, **348**:67-73.
99. Thapliyal R, Maru GB: Inhibition of cytochrome p450 isoenzymes by curcumins in vitro and in vivo. *Food Chem Toxicol* 2001, **39**:541-547.
100. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S: Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. *Pharmacol Toxicol* 2003, **92**:33-38.
101. Krishnaswamy K, Goud VK, Sesikeran B, Mukundan MA, Krishna TP: Retardation of experimental tumorigenesis and reduction in DNA adducts by turmeric and curcumin. *Nutr Cancer* 1998, **30**:163-166.
102. Inano H, Onoda M, Inafuku N, Kubota M, Kamada Y, Osawa T, Kobayashi H, Wakabayashi K: Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays. *Carcinogenesis* 1999, **20**:1011-1018.
103. Collett GP, Robson CN, Mathers JC, Campbell FC: Curcumin modifies Apc (min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc (min) mice. *Carcinogenesis* 2001, **22**:821-825.
104. Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. *J Cell Sci* 2004, **117**:5965-5973.
105. Hsu TC, Young MR, Cmarik J, Colburn NH: Activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB) dependent transcriptional events in carcinogenesis. *Free Radic Biol Med* 2000, **28**:1338-1348.
106. Shaulian E, Karin M: AP-1 in cell proliferation and survival. *Oncogene* 2001, **20**:2390-2400.
107. Passequé E, Wagner EF: JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. *EMBO J* 2000, **19**:2669-2679.
108. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, Aggarwal BB: Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. *Int J Cancer* 2009, **125**:2187-2197.
109. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM: Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. *Biochem Pharmacol* 2010, **79**:218-228.
110. Park CH, Lee JH, Yang CH: Curcumin derivatives inhibit the formation of Jun-Fos-DNA complex independently of their conserved cysteine residues. *J Biochem Mol Biol* 2005, **38**:474-480.
111. Sa G, Das T: Anti cancer effects of curcumin: cycle of life and death. *Cell Div* 2008, **3**:14.
112. Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. *Science* 1996, **274**:1664-1672.
113. Nurse P, Masui Y, Hartwell L: Understanding the cell cycle. *Nat Med* 1998, **4**:1103-1106.
114. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev* 1999, **13**:1501-1512.
115. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF: INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. *IUBMB Life* 2007, **59**:419-426.
116. Delston RB, Harbour JW: Rb at the interface between cell cycle and apoptotic decisions. *Curr Mol Med* 2006, **6**:713-718.
117. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. *Genes Dev* 1993, **7**:331-342.
118. Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, Lee SH, Hong SI: Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. *Int J Oncol* 2002, **21**:379-383.
119. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. *Cell Cycle* 2007, **6**:2953-2961.
120. Senderowicz AM: Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. *Cancer Chemother Pharmacol* 2003, **52**(Suppl 1):S61-73.
121. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependant kinases, and Cdk inhibitors in human cancer. *Adv Cancer Res* 1996, **68**:67-108.
122. Liu Q, Loo WT, Sze SC, Tong Y: Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. *Phytomedicine* 2009, **16**:916-922.
123. Singh M, Singh N: Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. *Mol Cell Biochem* 2009, **325**:107-119.
124. Wang Z, Desmoulin S, Banerjee S, Kong D, Li Y, Deraniyagala RL, Abbruzzese J, Sarkar FH: Synergistic effects of multiple natural products in pancreatic cancer cells. *Life Sci* 2008, **83**:293-300.
125. Wang Y, Okan I, Szekely L, Klein G, Wiman KG: Bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and Bax. *Cell Growth Differ* 1995, **6**:1071-1075.
126. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. *Cell* 1996, **86**:147-157.
127. Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependant manner. *J Biol Chem* 2005, **280**:20059-20068.
128. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P: Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. *Cancer Biol Ther* 2007, **6**:178-184.
129. Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X, Zhang X: Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. *J Neurooncol* 2007, **85**:263-270.
130. Gajate C, Mollinedo F: Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. *J Biol Chem* 2005, **280**:11641-11647.
131. Lu HF, Lai KC, Hsu SC, Lin HJ, Yang MD, Chen YL, Fan MJ, Yang JS, Cheng PY, Kuo CL, Chung JG: Curcumin induces apoptosis through FAS and FADD, in caspase-3-dependent and -independent pathways in the N18 mouse-rat hybrid retina ganglion cells. *Oncol Rep* 2009, **22**:97-104.
132. Bush JA, Cheung KJ Jr, Li G: Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. *Exp Cell Res* 2001, **271**:305-314.
133. Freudspurger C, Greten J, Schumacher U: Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB. *Anticancer Res* 2008, **28**:209-214.
134. Shankar S, Ganapathy S, Chen Q, Srivastava RK: Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. *Mol Cancer* 2008, **7**:16.
135. Singletary K, Milner J: Diet, autophagy and cancer: a review. *Cancer Epidemiol Biomarkers Prev* 2008, **17**:1596-1610.
136. Edinger AL, Thompson CB: Death by design: apoptosis, necrosis and autophagy. *Curr Opin Cell Biol* 2004, **16**:663-669.
137. Indelicato M, Pucci B, Schito L, Reali V, Aventaggiato M, Mazarino MC, Stivala F, Fini M, Russo MA, Tafani M: Role of hypoxia and autophagy in MDA-MB-231 invasiveness. *J Cell Physiol* 2010, **223**:359-368.
138. Kang C, Avery L: To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation. *Autophagy* 2008, **4**:82-84.
139. Alva AS, Gultekin SH, Baehrecke EH: Autophagy in human tumors: cell survival or death? *Cell Death Differ* 2004, **11**:1046-1048.

140. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V: **AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumor cells.** *J Cell Mol Med* 2009, **13**:3644-3654.
141. Li J, Qin Z, Liang Z: **The pro-survival role of autophagy in resveratrol-induced cytotoxicity in human U251 glioma cells.** *BMC Cancer* 2009, **9**:215.
142. Bellodi C, Lidonni MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B: **Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.** *J Clin Invest* 2009, **119**:1109-1123.
143. Namgoong GM, Khanal P, Cho HG, Lim SC, Oh YK, Kang BS, Shim JH, Yoo JC, Choi HS: **The prolyl-isomerase pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer.** *J Biol Chem* 2010, **285**:23829-23841.
144. Samadder JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, Browning D, Rawson J, Smith SB, Barrett JT, Schoenlein PV: **A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance.** *Mol Cancer Ther* 2008, **7**:2977-2987.
145. Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG, Huang LL, Zhu F, Wu G: **Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy.** *Cancer Biother Radiopharm* 2010, **25**:75-80.
146. Song J, Qu Z, Guo X, Zhao Q, Zhao X, Gao L, Sun K, Shen F, Wu M, Wei L: **Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells.** *Autophagy* 2009, **5**:1131-1144.
147. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B: **Induction of autophagy and inhibition of tumorigenesis by beclin 1.** *Nature* 1999, **402**:672-676.
148. Yue Z, Jin S, Yang C, Levine AJ, Heintz N: **Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor.** *Proc Natl Acad Sci USA* 2003, **100**:15077-15082.
149. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, Levine B: **Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.** *J Clin Invest* 2003, **112**:1809-1820.
150. Bursch W, Ellinger A, Kienzl H, Török L, Pandey S, Sikorska M, Walker R, Hermann RS: **Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy.** *Carcinogenesis* 1996, **17**:1595-1607.
151. Górka M, Daniewski WM, Gajkowska B, Lusakowska E, Godlewski MM, Motyl T: **Autophagy is the dominant type of programmed cell death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new sesquiterpene analogs of paclitaxel.** *Anticancer Drugs* 2005, **16**:777-788.
152. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I: **Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.** *Cancer Res* 2003, **63**:2103-2108.
153. Qian W, Liu J, Jin J, Ni W, Xu W: **Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.** *Leuk Res* 2007, **31**:329-339.
154. Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ: **Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis.** *Autophagy* 2010, **6**:353-365.
155. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer HP, Schätzl HM: **The anticancer drug imatinib induces cellular autophagy.** *Leukemia* 2007, **21**:936-942.
156. Basciani S, Vona R, Matarrese P, Ascione B, Mariani S, Cauda R, Gnassi L, Malorni W, Straface E, Lucia MB: **Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells.** *FEBS Lett* 2007, **581**:5897-5903.
157. Katayama M, Kawaguchi T, Berger MS, Pieper RO: **DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.** *Cell Death Differ* 2007, **14**:548-558.
158. Gewirtz DA, Hilliker ML, Wilson EN: **Promotion of autophagy as a mechanism for radiation sensitization of breast cancer cells.** *Radiother Oncol* 2009, **92**:323-328.
159. Zhuang W, Qin Z, Liang Z: **The role of autophagy in sensitizing malignant glioma cells to radiation therapy.** *Acta Biochim Biophys Sin (Shanghai)* 2009, **41**:341-351.
160. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, Kalkanis SN, Mikkelsen T, Brodie C: **The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells.** *Int J Cancer* 2009, **125**:717-722.
161. Jia YL, Li J, Qin ZH, Liang ZQ: **Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells.** *J Asian Nat Prod Res* 2009, **11**:918-928.
162. O'Sullivan-Coyne G, O'Sullivan GC, O'Donovan TR: **Curcumin induces apoptosis-independent death in oesophageal cancer cells.** *Br J Cancer* 2009, **101**:1585-1595.
163. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y: **Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.** *Mol Pharmacol* 2007, **72**:29-39.
164. Shinjima N, Yokoyama T, Kondo Y, Kondo S: **Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy.** *Autophagy* 2007, **3**:635-637.
165. Cao Y, Liu Q: **Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.** *Adv Cancer Res* 2007, **97**:203-224.
166. Barrascout E, Medioni J, Scotte F: **Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab.** *Bull Cancer* 2010, **97**:29-43.
167. Perry MC, Demeule M, Régina A, Moudjian R, Béliveau R: **Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts.** *Mol Nutr Food Res* 2010.
168. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S: **Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice.** *World J Gastroenterol* 2008, **14**:2003-2009.
169. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK: **Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.** *Clin Cancer Res* 2007, **13**:3423-3430.
170. Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP: **Molecular mechanisms of anti-angiogenic effect of curcumin.** *Biochem Biophys Res Commun* 2002, **297**:934-942.
171. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME: **Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B.** *J Biol Chem* 2000, **275**:10405-10412.
172. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S: **Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice.** *Clin Hemorheol Microcirc* 2006, **34**:109-115.
173. Ray S, Chattopadhyay N, Mitra A, Siddiqi M, Chatterjee A: **Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin.** *J Environ Pathol Toxicol Oncol* 2003, **22**:49-58.
174. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA: **Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways.** *Cancer Res* 2008, **68**:3645-3654.
175. Yodkeeree S, Ampasavate C, Sung B, Aggarwal BB, Limtrakul P: **Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line.** *Eur J Pharmacol* 2010, **627**:8-15.
176. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE: **Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.** *Clin Cancer Res* 2005, **11**:7490-7498.
177. Chakravarti N, Myers JN, Aggarwal BB: **Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).** *Int J Cancer* 2006, **119**:1268-1275.
178. Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R: **Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells.** *Cancer Prev Res* 2010, **3**:331-338.
179. Chang KW, Hung PS, Lin IY, Hou CP, Chen LK, Tsai YM, Lin SC: **Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression.** *Int J Cancer* 2010, **127**:9-20.

180. Cohen AN, Veena MS, Srivatsan ES, Wang MB: **Suppression of Interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of I kappa beta kinase.** *Arch Otolaryngol Head Neck Surg* 2009, **135**:190-197.
181. Lin L, Hutzen B, Ball S, Foust E, Foust E, Sobo M, Deangelis S, Pandit B, Friedman L, Li C, Li PK, Fuchs J, Lin J: **New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells.** *Cancer Sci* 2009, **100**:1719-1727.
182. Crowell JA, Steele VE, Fay JR: **Targeting the AKT protein kinase for cancer chemoprevention.** *Mol Cancer Ther* 2007, **6**:2139-2148.
183. Bisht S, Maitra A: **Systemic delivery of curcumin: 21st century solutions for an ancient conundrum.** *Curr Drug Discov Technol* 2009, **6**:192-199.
184. Li L, Braithe FS, Kurzrock R: **Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.** *Cancer* 2005, **104**:1322-1331.
185. Li L, Ahmed B, Mehta K, Kurzrock R: **Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer.** *Mol Cancer Ther* 2007, **6**:1276-1282.
186. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA: **Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.** *Anticancer Res* 2009, **29**:1895-1899.
187. Clark CA, McEachern MD, Shah SH, Rong Y, Rong X, Smelley CL, Caldito G, Abreo F, Nathan CA: **Curcumin Inhibits Carcinogen and Nicotine-induced Mammalian Target of Rapamycin Pathway Activation in Head and Neck Squamous Cell Carcinoma.** *Cancer Prev Res* 2010, **3**:1586-1595.
188. Duarte VM, Han EH, Veena MS, Salvado A, Suh JD, Liang L-J, Faull KF, Srivatsan ES, Wang MB: **Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of I kappa B protein of the nuclear factor kappa B.** *Mol Cancer Ther* 2010, **9**:2665-2675.
189. Khafif A, Lev-Ari S, Vexler A, Barnea I, Starr A, Karaush V, Haif S, Ben-Yosef R: **Curcumin: a potential radio-enhancer in head and neck cancer.** *Laryngoscope* 2009, **119**:2019-2026.
190. Jagetia JC: **Radioprotection and radiosensitization by curcumin.** *Adv Exp Med Biol* 2007, **595**:301-320.
191. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM: **Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3.** *Oncogene* 2004, **23**:1599-1607.
192. Sandur SK, Deorukhkar A, Pandey MK, Pabón AM, Shentu S, Guha S, Aggarwal BB, Krishnan S: **Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity.** *Int J Radiat Oncol Biol Phys* 2009, **75**:534-542.
193. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC: **Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.** *J Ovarian Res* 2010, **3**:11.
194. Al-Haji M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: **Prospective identification of tumorigenic breast cancer cells.** *Proc Natl Acad Sci USA* 2006, **100**:3983-3988.
195. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: **A cell initiating human acute myeloid leukemia after transplantation into SCID mice.** *Nature* 2004, **17**:645-648.
196. Prince ME, Sivanadan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: **Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.** *Proc Natl Acad Sci USA* 2007, **104**:973-978.
197. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: **Prospective identification of tumorigenic prostate cancer cells.** *Cancer Res* 2005, **65**:10946-10951.
198. Kondo T, Setoguchi T, Taga T: **Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line.** *Proc Natl Acad Sci USA* 2004, **101**:781-786.
199. O'Brien CA, Pollett A, Gallinger S, Dick JE: **A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.** *Nature* 2007, **445**:111-115.
200. Harper L, Piper K, Common J, Fortune F, Mackenzie IC: **Stem cell patterns in cell lines derived from head & neck squamous cell carcinoma.** *J Oral Pathol Med* 2007, **36**:594-603.
201. Wu A, Veena MS, Basak SA, Wang MB, Srivatsan ES: **CD44^{High} head and neck cancer cells demonstrate increased cell growth and chemotherapeutic resistance [Abstract].** *Amer Assoc Cancer Res* 2010, **51**:s3316.
202. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A: **Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.** *J Clin Oncol* 2006, **24**:2866-2872.
203. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F: **Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.** *Differentiation* 2007, **75**:788-799.
204. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR: **Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.** *Clin Cancer Res* 2006, **12**:5064-5073.
205. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: **Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.** *J Clin Oncol* 2004, **22**:77-85.
206. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Giorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE: **Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck.** *J Clin Oncol* 2009, **27**:1864-1871.
207. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Linggen MW, Olopade OI, Vokes EE: **Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.** *J Clin Oncol* 2010, **28**:3336-3343.
208. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M: **Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.** *Oncol Rep* 2007, **18**:47-51.
209. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancy JE, Stenson K, Blair E, Dekker A, Vokes EE: **Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase II study.** *Lancet Oncol* 2009, **10**:247-257.
210. Bussink J, van der Kogel AJ, Kaanders JH: **Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.** *Lancet Oncol* 2008, **9**:288-296.
211. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G: **Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.** *Cancer Res* 2007, **67**:2160-2168.
212. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J, Nathan CO: **Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.** *Mol Cancer Ther* 2009, **8**:2255-2265.
213. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: **Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.** *Cancer Res* 2006, **66**:11851-11858.
214. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG: **Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.** *J Clin Oncol* 2010, **28**:3330-3335.
215. Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB: **Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.** *Cancer Chemother Pharmacol* 2009, **64**:233-241.
216. Fury MG, Haque S, Stambuk H, Shen R, Carlson D, Pfister D: **A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.** *Cancer* 2010.

217. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C: **Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor- κ B subunits in head and neck cancer.** *Clin Cancer Res* 2008, **14**:4175-4185.
218. Li C, Li R, Grandis JR, Johnson DE: **Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.** *Mol Cancer Ther* 2008, **7**:1647-1655.
219. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA: **Nuclear factor- κ B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.** *Ann Oncol* 2010, **21**:864-870.

doi:10.1186/1476-4598-10-12

Cite this article as: Wilken *et al.*: Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. *Molecular Cancer* 2011 **10**:12.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

